Sobczyńska-Rak Aleksandra, Brodzki Adam
Department and Clinic of Animal Surgery, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Lublin, Poland
Department and Clinic of Animal Surgery, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Lublin, Poland.
In Vivo. 2014 Sep-Oct;28(5):871-7.
The aim of the present study was to determine the serum levels of vascular endothelial growth factor in animals in the course of pharmacological treatment against perianal gland neoplasms. Research material comprised of tumor tissue samples obtained from 30 dogs and blood drawn from dogs with tumors and control group animals. The neoplasm type was determined in accordance with the relevant WHO classification. Immunoenzimatic determination of VEGF levels in the blood sera was performed. In all studied animals suffering from tumors, pharmacological tamoxifen treatment was administered, at a dosage of 2 mg/kg bodyweight. The medication was administered for one month. In order to monitor the serum levels of 17-β-estradiol and VEGF, blood was drawn from sick animals three times (on the day of the diagnosis, as well as at one and six months after treatment). The VEGF determination assay was performed in accordance with the manufacturer's guidelines for the ELISA. In the studied group, 12 animals were diagnosed with hepatoid gland adenomas and 18 with hepatoid gland epitheliomas. Elevated VEGF levels were observed in the group of dogs with hepatoid gland ephithelioma in comparison with the control group. In the studied groups, a decrease in serum VEGF level and a complete remission of neoplastic lesions was observed one month after administering tamoxifen. The VEGF levels in dogs with hepatoid gland adenoma continued to decline with time. In the case of dogs with hepatoid gland epithelioma, after the initial drop one month after treatment, a rapid increase of the growth factor level was observed, which was significantly higher in animals suffering a relapse of the neoplastic disease (50% of dogs). A significant correlation was observed between 17-β-estradiol and VEGF levels in dogs with hepatoid gland epithelioma on the day of diagnosis (Rxy=0.64, p<0.05) and six months after treatment (Rxy=0.54, p<0.05). Conclusion: VEGF overexpresion observed six months after tamoxifen treatment may constitute a prognostic factor in terms of the progression of the neoplastic process. The level of VEGF correlates with the level of 17-β-estradiol in serum. Apart from anti-estrogen effects, tamoxifen also demonstrates anti-angiogenic activity.
本研究的目的是测定在针对肛周腺肿瘤进行药物治疗过程中动物血清中血管内皮生长因子的水平。研究材料包括从30只狗身上获取的肿瘤组织样本以及从患有肿瘤的狗和对照组动物身上抽取的血液。肿瘤类型根据世界卫生组织的相关分类确定。对血清中VEGF水平进行免疫酶法测定。在所有研究的患有肿瘤的动物中，给予他莫昔芬药物治疗，剂量为2mg/kg体重。给药一个月。为了监测17-β-雌二醇和VEGF的血清水平，从患病动物身上抽取三次血液（诊断当天以及治疗后1个月和6个月）。VEGF测定试验按照酶联免疫吸附测定（ELISA）试剂盒制造商的指南进行。在研究组中，12只动物被诊断为肝样腺腺瘤，18只被诊断为肝样腺上皮瘤。与对照组相比，肝样腺上皮瘤组的狗VEGF水平升高。在研究组中，给予他莫昔芬1个月后，血清VEGF水平下降，肿瘤病变完全缓解。肝样腺腺瘤狗的VEGF水平随时间持续下降。对于肝样腺上皮瘤的狗，在治疗1个月后最初下降后，观察到生长因子水平迅速升高，在肿瘤疾病复发的动物（50%的狗）中显著更高。在诊断当天（Rxy = 0.64，p < 0.05）和治疗后6个月（Rxy = 0.54，p < 0.05），肝样腺上皮瘤的狗中17-β-雌二醇和VEGF水平之间观察到显著相关性。结论：他莫昔芬治疗6个月后观察到的VEGF过表达可能构成肿瘤进程进展的一个预后因素。VEGF水平与血清中17-β-雌二醇水平相关。除了抗雌激素作用外，他莫昔芬还表现出抗血管生成活性。
